logo
ANHUI BBCA PHARMACEUTICAL CO.,LTD
ANHUI BBCA PHARMACEUTICAL CO.,LTD
продукты
Домой /

продукты

Glucose Injections, Plastic Bottle, soft bag, 5%10% For Pain Colorless or colorless clear liquid

Подробная информация о продукции

Место происхождения: Китай

Фирменное наименование: BBCA

Сертификация: GMP

Условия оплаты и доставки

Количество мин заказа: 10000/20000/30000

Цена: 0.1-1USD/bottle/carton

Упаковывая детали: стеклянная бутылка/ полипропиленовая бутылка для инфузий/ трехслойный коэкструдированный пакет для и

Время доставки: 5-8 дней

Условия оплаты: L/C, T/T

Поставка способности: партии 10000/20000/30000

Лучшая цена
Свяжитесь сейчас
Спецификации
Выделить:
Уровень:
Медицинология
внешний вид:
Бесцветная или бесцветная прозрачная жидкость
Спецификация:
100 мл/250 мл/500 мл 5%, 10%
Упаковка:
пластиковая бутылка/мягкий пакет
Уровень:
Медицинология
внешний вид:
Бесцветная или бесцветная прозрачная жидкость
Спецификация:
100 мл/250 мл/500 мл 5%, 10%
Упаковка:
пластиковая бутылка/мягкий пакет
Описание
Glucose Injections, Plastic Bottle, soft bag, 5%10% For Pain Colorless or colorless clear liquid

 

 

Pharmaceutical Transfusion Medicine Glass Bottle Packing Ofloxacin And Glucose Injection

Basic Information:

Product Name Glucose Injection
Component Glucose and water
Appearance: Colorless or colorless clear liquid

 

Indications:

Suitable for sensitive bacteria caused by:
1. Urinary reproductive system infection, including simple and complicated urinary tract infection, bacterial prostatitis, bacteria neisseria gonorrhea urethritis and cervicitis (including enzyme production strains caused by).
2. Respiratory tract infections, including sensitive acute bronchial infection caused by gram-negative bacilli and lung infection.
3. Gastrointestinal tract infection, by shigella, salmonella and e. coli to produce enterotoxin, moisture, deputy hemolytic bacterium vibrio, etc.
4. Typhoid.
5. Bone and joint infections.
6. Skin soft tissue infection.
7. Sepsis and systemic infection.

 

Specifications: 

5% 50ml 2.5g 100ml 5g 250ml 12.5g 500ml 25g
10% 50ml 5g 100ml 10g 250ml 25g 500ml 50g

 

 

Usage and Dosage:

Intravenous drip slowly.Adults often usage:
1.Bronchial infection, pulmonary infection: a 0.3 g, 2 times a day, treatment 7 ~ 14 days.
2.Acute simple lower urinary tract infection: a 0.2 g, 2 times a day, course of 5 to 7 days;Complexity urinary tract infection: a 0.2 g, 2 times a day, 10 ~ 14.
3.Prostatitis: a 0.3 g, 2 times a day, the course of six weeks;Chlamydia cervicitis or urethritis, a 0.3 g, 2 times a day, the course of 7 ~ 14 days.
4.Simple gonorrhea: 0.4 g at a time, a single dose.
5.Typhoid fever: a 0.3 g, 2 times a day, course of 10 ~ 14.
6.Pseudomonas aeruginosa infection or heavier infection: dose may be increased to 0.4 g, 2 times a day.

 

Drug interactions:

 

1.Urine, agents can reduce the product solubility in the urine, cause crystallization urine and kidney toxicity.
2.Quinolone antibacterial and theophylline class share may be due to combined with the cytochrome P450 when parts of a competitive inhibition, seriously reduce the liver to eliminate theophylline class, blood elimination half-life (t1/2 beta), blood drug concentration increases, theophylline poisoning symptoms, such as nausea, vomiting, tremor, anxiety, excitement, convulsions, heart palpitations and so on.Metabolic effects of theophylline, although small, but share when should still determination of theophylline blood drug concentration and dose adjustment.
3.This product with ring spore share, can make the ring spore elevated blood drug concentration, must monitor ring spore blood concentration, and adjust the dosage.
4.This product and share the anti-clotting drug warfarin is smaller in the latter the anticoagulant effect of enhanced, but also should closely monitor patients when sharing the prothrombin time.
5.Probenecid can reduce the product since the renal tubular secretion by about 50%, when share can produce because of the product increased blood levels of toxicity.

 

Contraindications: This article and fluoroquinolone drug allergy patients disabled.

 

Pharmacological mechanisms: The product widely distributed to the group after the treatment, body fluids, organizations often more than the concentration of blood drug concentration and effective level.This product can be through the placental barrier.Protein binding rate of 20% ~ 25%.
This product mainly prototype medicine since renal excretion, a small amount (3%) in hepatic metabolism.Urine metabolites are rare.This product to prototype from feces to remove a small amount, 24 hours a day and 48 hours after the treatment the cumulative discharge of dosage of 1.6% and 1.6% respectively.This product can also be through breast milk secretion.

 

Storage: Protect from light, airtight preservation.

 

Package: 30 /40/100 Plastic bottles/carton

Аналогичные продукты
Отправьте запрос
Пожалуйста, отправьте нам свой запрос, и мы ответим вам как можно скорее.
Отправить